B. Riley analyst Anderson Schock downgraded ZimVie (ZIMV) to Neutral from Buy with a price target of $19, up from $16, after the company entered into a definitive agreement to be acquired by Archimed for $19 per share in cash. While the 40 day go-shop period creates potential for superior offers, the closing of the Archimed deal is the most probable outcome, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV:
- ZimVie Inc. Reports Q2 2025 Results Amid Acquisition
- ZimVie withdraws guidance amid ARCHIMED transaction
- ZimVie will not host withdraws guidance amid ARCHIMED transaction
- ZimVie announces exclusive distribution agreement with Osstem Implant in China
- ZimVie upgraded to Equal Weight from Underweight at Barclays